ERBB2 and cancer: Although molecular subtypes affect prognosis, this plays less of a role in the overall prevalence of lymph node metastases, with 31% for ER+/HER2-, 34% for triple negative(ER-/PR-/HER2-) and 40% for HER2+ cancers.